RANI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Rani Therapeutics is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading below its pivot with weakening momentum, no proprietary buy signal, and recent financing news that adds dilution pressure. Even though analysts still keep a Buy rating, the sharply lowered target and the recent offering make the setup unattractive for an impatient investor seeking a clear entry today.
Technically, RANI is weak in the short term. The pre-market price is 0.9598, below the pivot level of 1.011 and only slightly above S1 at 0.911. MACD is negative and expanding lower, which confirms bearish momentum. RSI_6 at 42 is neutral but not strong enough to signal a bounce. Moving averages are converging, which suggests indecision rather than a confirmed uptrend. Overall, the chart does not show a strong buy setup right now.
["Canaccord still maintains a Buy rating on the shares.", "The company announced initiation of a Phase I clinical study in Australia for RT-114, a GLP-1/GLP-2 dual agonist for obesity.", "Recent quarterly results showed revenue of $1.7 million, ahead of expectations by $1.2 million.", "Pre-market price is slightly positive, suggesting mild short-term stability."]
["Rani announced a direct offering of 12.48 million shares at $1.07 and 6.21 million pre-funded warrants, which is dilutionary.", "Canaccord lowered its price target from $9 to $5, a meaningful cut in upside expectations.", "MACD is negative and worsening, indicating deteriorating momentum.", "Similar-pattern trend data points to negative expected returns over the next day, week, and month.", "Hedge funds and insiders are neutral with no notable buying support.", "No AI Stock Picker or SwingMax signal is present today.", "No recent congress trading data is available."]
Latest reported quarter: 4Q25 / FY2025. The company reported GAAP EPS of -$0.04 and revenue of $1.7 million, with revenue beating expectations by $1.2 million. The beat is positive, but the business remains loss-making and the new capital raise suggests ongoing funding needs rather than strong self-sustaining growth.
Analyst sentiment is mixed-to-positive but weakening. Canaccord kept a Buy rating, but cut the price target sharply from $9 to $5 after the company’s 4Q25 and FY2025 results. That means Wall Street still sees upside potential, but expectations have been reset lower. Pros: Buy rating remains intact and clinical pipeline progress supports a speculative upside case. Cons: the target cut is large, and the latest financing dilutes the equity story.
